|Bid||19.96 x 500|
|Ask||22.84 x 3000|
|Day's Range||20.40 - 21.49|
|52 Week Range||11.30 - 27.86|
|PE Ratio (TTM)||-22.24|
|Earnings Date||Nov 6, 2017 - Nov 10, 2017|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||37.00|
The presentations will comprise ralinepag IP receptor binding affinity, selectivity and comparative functional potency versus approved IP agonists. Biological responses highlighting the pharmacology and pharmacokinetics of ralinepag in rat PAH models, human platelets, human pulmonary arteries and human pulmonary artery smooth muscle cells from PAH patients will be presented.
Q2 2017 Arena Pharmaceuticals Inc Earnings Call
Top-line results from this midstage study was the shot in the arm that Arena's shareholders needed.